Cyclo Therapeutics, Inc

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Companys Trappsol CycloTM, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is conducting a Phase 2b clinical trial using Trappsol CycloTM intravenously in early Alzheimers disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimers disease (NCT03624842). Additional indications for the active...

Cyclodextrins,cyclodextrin derivatives,cyclodextrin complexes,cyclodextrin chemistry,hydroxypropyl,gamma,trappsol(r),cyclo(tm),and aquaplex(r)

Cyclo therapeutics, inc operates in the Pharmaceutical manufacturing industry.

Cyclo therapeutics, inc's revenue is < 1m

Cyclo therapeutics, inc has 11 - 50 employees.